These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14722893)

  • 1. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy.
    Fischer M; Joos B; Wong JK; Ott P; Opravil M; Hirschel B; Weber R; Günthard HF;
    J Infect Dis; 2004 Jan; 189(2):273-85. PubMed ID: 14722893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts.
    Fischer M; Wong JK; Russenberger D; Joos B; Opravil M; Hirschel B; Trkola A; Kuster H; Weber R; Günthard HF;
    Antivir Ther; 2002 Jun; 7(2):91-103. PubMed ID: 12212929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF;
    J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
    Parera M; Ibañez A; Clotet B; Martinez MA
    J Infect Dis; 2004 Apr; 189(8):1444-51. PubMed ID: 15073682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART.
    Potter SJ; Lemey P; Dyer WB; Sullivan JS; Chew CB; Vandamme AM; Dwyer DE; Saksena NK
    Virology; 2006 Apr; 348(1):35-46. PubMed ID: 16455126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART.
    Avettand-Fenoel V; Hocqueloux L; Müller-Trutwin M; Prazuck T; Melard A; Chaix ML; Agoute E; Michau C; Rouzioux C
    J Med Virol; 2011 Sep; 83(9):1499-507. PubMed ID: 21739438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
    Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
    J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective rev response element (RRE) and rev gene in HAART treated AIDS patients with discordance between viral load and CD4+ T-cell counts.
    Saurya S; Lichtenstein Z; Karpas A
    J Clin Virol; 2005 Aug; 33(4):324-7. PubMed ID: 16005679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
    J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH
    Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.